

## Sale of shares by the Executive Chairman and by the CEO to Fund Option Exercise

**PERTH, Australia, 12 June 2026:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix<sup>®</sup> AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease, advises that on 11 June 2026 an entity associated with Bernie Ridgeway sold 300,000 shares. The proceeds are intended to fund the exercise of 750,000 options, exercisable at \$1 per option and reimburse funding advanced for the exercise of 500,000 options at \$1 per option (refer ASX announcement 14 April, 2026).

On 11 June 2026, an entity associated with Co-Founder and Chief Executive Officer, John Konstantopoulos sold 770,000 shares to fund the exercise of 1,000,000 options exercisable at \$1 per option and meet tax obligations.

The options mentioned above expire on 9 July 2026 and were outlined in the IPO Prospectus and issued as part of the Company's management incentive program. The Company will advise the market on exercise of the above options and issuance of corresponding shares.

A Change of Director's Interest Notice will follow this announcement.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](https://www.linkedin.com/company/artrya)

For more information:

#### Corporate Enquiries

**John Konstantopoulos**

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

#### Investor & Media Enquiries

**David Allen or John Granger**

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.